Sign in
WithdrawnPhase 3

A Phase 3 Study Evaluating the Safety and Efficacy of Denifanstat in Patients With MASLD and MASH

Key facts

Who runs it
Sagimet Biosciences Inc.
Trial code
Status
Withdrawn
Phase
Phase 3
Started
Mar 2025
Expected to end
Jun 2027
Type of study
Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
Treatments tested
  • denifanstat
  • Placebo
Record updated
15 May 2025
Why it stopped
Business decision

Who can take part

Age
18 years to 75 years
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 43 criteriaShow less

Who can take part

  • Willing and able to participate in the study and provide written informed consent
  • Adults between 18 and 75 years of age
  • Body mass index (BMI) ≥23 kg/m2 for Asian patients and ≥25 kg/m2 for patients of other races
  • Presence of metabolic risk factor(s), as follows:
  • T2DM; OR
  • At least 2 out of 4 of the following:; BMI ≥30 kg/m2,; Hypertension, or on active antihypertensive treatment; Elevated fasting serum TGs or on active treatment for hypertriglyceridemia; Reduced fasting serum HDL-c, or on active treatment for dyslipidemia
  • For patients with T2DM:
  • HbA1c ≤9.5%
  • If treatment naive: patients must have been diagnosed for at least 12 weeks prior to screening
  • Suspected or confirmed diagnosis of MASH or MASLD or non-invasively diagnosed MASH or MASLD
  • Stable ALT and AST levels

Who cannot take part

  • Previous intake of an approved MASH medication
  • History of excessive alcohol intake for a period of more than 3 consecutive months within 1 year prior to screening
  • Prior or planned bariatric surgery
  • Gain or loss of >5% of body weight in the 3 months or >10% of body weight in the 6 months prior to screening, qualifying liver biopsy, and the baseline visit (V1)
  • Any of the following conditions or procedures within 6 months prior to the baseline visit (V1):
  • Malignancy with a complete remission date within 5 years prior to the baseline visit (V1)
  • Use of a nonpermitted concomitant medication within 30 days or 5 half-lives prior to screening
  • Presence of cirrhosis on liver histology and/or cross-sectional imaging evidence consistent with cirrhosis and/or portal hypertension
  • Evidence of another form of active liver disease
  • Positive serologic evidence of current infectious liver disease
  • Planned or history of liver transplantation
  • Myocardial infarction
  • Cardiac revascularization surgery
  • Unstable angina
  • Transient ischemic attack, stroke, or cerebrovascular disease
  • Unstable or undiagnosed arrhythmias
  • Any current or history of hepatocellular carcinoma
  • Diabetes other than T2DM
  • Any other known serious disease or other disease which in the Investigator's opinion would exclude the patient from participating in the study
  • Exclusionary laboratory values:
  • ALT and/or AST >5 × ULN
  • ALP ≥2 × ULN
  • Total serum bilirubin concentration >1.3 mg/dL
  • Serum albumin concentration <3.5 g/dL
  • International normalized ratio (INR) >1.3, except for patients receiving anticoagulant treatment
  • Platelet count <140,000/μL
  • Fasting TG level ≥500 mg/dL
  • eGFR <45 mL/min/1.73 m2
  • Current or historical clinically evident hepatic decompensation
  • MELD score ≥12
  • Uncontrolled high BP
  • Uncontrolled hypothyroidism

About the trial

What the trial wants to find out

A phase 3, randomized, double-blind, placebo-controlled study evaluating the safety and tolerability of denifanstat 50 mg compared to placebo in patients with metabolic dysfunction-associated steatotic liver disease (MALSD)/metabolic dysfunction-associated steatohepatitis (MASH) after 52 weeks of treatment.

The 2 groups in the trial

  • Denifanstat 50 mgTreatment being tested

    Denifanstat tablet, orally, once daily

    Treatment: denifanstat

  • PlaceboPlacebo, for comparison

    Placebo tablet, orally, once daily

Saves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Denifanstat in Patients With Metabolic Dysfunction-Associated Steatotic Liver Disease (MALSD)/Metabolic Dysfunction-Associated Steatohepatitis (MASH)
Record updated
15 May 2025